Profusa, Inc. (NASDAQ:PFSA – Get Free Report) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 123,461 shares, a decrease of 57.2% from the May 31st total of 288,318 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily volume of 412,104 shares, the days-to-cover ratio is currently 0.3 days.
Analysts Set New Price Targets
Several research firms have commented on PFSA. Wall Street Zen raised Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research report on Wednesday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
View Our Latest Report on PFSA
Profusa Price Performance
Profusa (NASDAQ:PFSA – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($2.05) earnings per share (EPS) for the quarter.
About Profusa
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
Featured Articles
- Five stocks we like better than Profusa
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
